These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33235024)

  • 1. Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia.
    Tasaki M; Yasui-Furukori N; Kubo K; Yokoyama S; Shinozaki M; Sugawara N; Inoue Y; Shimoda K
    Ther Drug Monit; 2021 Aug; 43(4):589-592. PubMed ID: 33235024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
    Tasaki M; Yasui-Furukori N; Yokoyama S; Shinozaki M; Sugawara N; Shimoda K
    Neuropsychopharmacol Rep; 2021 Sep; 41(3):379-384. PubMed ID: 34189861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Nagai G; Kagawa S; Nemoto K; Ohta I; Arakaki H; Uno T; Kondo T
    Ther Drug Monit; 2011 Feb; 33(1):21-4. PubMed ID: 21157400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
    Nagai G; Mihara K; Nakamura A; Nemoto K; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2017 Feb; 39(1):62-65. PubMed ID: 27861318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents.
    Ma B; Zhao W; Fan H; Yun Y; Qi S; An H; Yang F
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):27-33. PubMed ID: 36730747
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
    Nakamura A; Mihara K; Nemoto K; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):815-8. PubMed ID: 24739668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia.
    Bachmann CJ; Rieger-Gies A; Heinzel-Gutenbrunner M; Hiemke C; Remschmidt H; Theisen FM
    Ther Drug Monit; 2008 Aug; 30(4):462-6. PubMed ID: 18641558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
    Lin SK; Chen CK; Liu YL
    J Clin Psychopharmacol; 2011 Dec; 31(6):758-62. PubMed ID: 22020350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Nemoto K; Mihara K; Nakamura A; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2012 Apr; 34(2):188-92. PubMed ID: 22377745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis.
    Propst AJ; Jarvis GE; Margolese HC
    Clin Schizophr Relat Psychoses; 2016; 9(4):173-6. PubMed ID: 25711510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.
    Koller D; Belmonte C; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):236-246. PubMed ID: 31520576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
    Kirschbaum KM; Müller MJ; Malevani J; Mobascher A; Burchardt C; Piel M; Hiemke C
    World J Biol Psychiatry; 2008; 9(3):212-8. PubMed ID: 17853280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
    Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
    BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients.
    Huang HC; Liu CH; Lan TH; Hu TM; Chiu HJ; Wu YC; Tseng YL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):57-61. PubMed ID: 17602901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.